Table 3.

Univariate survival analysis of 99 patients with extremity soft tissue sarcoma

	No.	5-year OS		5-year DFS		5-year LRFS		5-year DMFS
		%	P value	%	P value	%	P value	%	P value
Age (years)
≤ 60	74	85.9	< 0.001	77.4	0.001	89.4	0.236	84.4	0.002
> 60	25	52.0		43.2		83.6		55.7
Tumor size (cm)
≤ 5	34	87.5	0.130	78.0	0.229	96.7	0.162	84.2	0.263
> 5	61	69.8		63.5		82.3		71.8
Tumor depth
Superficial	30	89.3	0.205	79.0	0.300	92.6	0.734	86.2	0.296
Deep	69	71.9		65.8		86.2		73.2
FNCLCC grade
1–2	67	84.8	0.012	81.5	< 0.001	93.4	0.008	84.5	0.003
3	32	60.2		44.8		75.3		61.4
Resection margin
Negative	77	80.0	0.065	73.6	0.109	93.9	0.001	78.9	0.202
Close or Positive	19	67.4		52.6		65.1		68.0
Chemotherapy
No	58	80.2	0.522	73.0	0.535	86.0	0.313	84.0	0.115
Yes	41	72.7		65.5		91.5		67.9
Hemoglobin (g/dL)
≥ 12	84	76.7	0.914	68.0	0.398	87.5	0.574	76.6	0.765
< 12	15	79.4		80.0		93.3		80.0
CRP (mg/dL)
≤ 0.14	61	84.5	0.050	79.3	0.023	92.6	0.376	84.5	0.015
> 0.14	33	69.3		57.1		84.1		66.5
ESR (mm/h)
≤ 15	47	91.2	0.001	89.1	0.003	97.7	0.035	93.5	0.001
> 15	44	69.4		57.8		80.6		67.4
NLR
≤ 1.95	52	84.0	0.054	78.4	0.174	89.3	0.793	84.4	0.170
> 1.95	45	70.2		63.0		89.0		69.9

Abbreviations: OS overall survival, DFS disease-free survival, DMFS distant metastasis-free survival, LRFS local recurrence-free survival, FNCLCC Fédération Nationale des Centres de Lutte Contre le Cancer, CRP C-reactive protein, ESR erythrocyte sedimentation rate, NLR neutrophil to lymphocyte ratio